Geroscience Grows Up: Inside the Quiet Shift to Precision Geromedicine

For years, two big frameworks shaped how scientists thought about aging. One, called SENS (short for Strategies for Engineered Negligible Senescence), treated aging like rust on a car: identify the damage, repair it, repeat. The other, the Hallmarks of Aging, mapped out a dozen-ish core biological processes — things like cellular senescence, mitochondrial dysfunction, and stem cell exhaustion — that seem to drive the whole show. A new comparison in Biogerontology walks through both side by side, arguing the two camps share more than their fans admit, and that their disagreements are often about definitions, evidence standards, and communication style rather than incompatible biology.

That matters because the field's next chapter doesn't really belong to either camp. In April 2025, a who's-who of aging biologists published a synthesis in Cell proposing a cleaner vocabulary: aging, they argue, is pushed forward by 'gerogenes' and held back by 'gerosuppressors' — borrowing the logic of oncogenes and tumor suppressors from cancer biology. It's a small linguistic move with big implications. If you can name the genes and pathways that accelerate aging, you can, in principle, drug them. And if you can name the ones that protect against aging, you can try to boost them.

The Cell authors call this next phase precision geromedicine. The pitch: instead of one-size-fits-all 'anti-aging' supplements, future gerotherapeutics would be matched to a person using their genetic profile, omics-based aging biomarkers, clinical and digital signals, and even psychosocial context. Think less 'take this pill at 50,' more 'your particular aging trajectory looks like this, so we'd target that.'

Important caveat, because the evidence here is genuinely moderate, not slam-dunk: the Cell authors are explicit that any actual rollout depends on randomized clinical trials and regulatory approval that mostly haven't happened yet. The framework is real. The pharmacy shelf isn't.

If the Cell paper is the theory, the lab benches are where it gets tested. A report from the Fifth Annual Midwest Aging Consortium symposium, held at Ohio State in April 2024, gives a useful snapshot of where research energy is going: cellular senescence and the aging brain, metabolic interventions, nutrition, redox biology and biomarkers, and stress mechanisms. None of those are flashy on TikTok. All of them feed directly into the precision-geromedicine pipeline.

The industry side is moving in parallel. A 2024 review in Aging, co-authored by an unusually long list of academics and biotech founders, frames the field as a convergence of artificial intelligence, biomarkers and aging clocks, geroscience, and clinical trials. Their argument, in plain English: AI is getting good enough to spot patterns in biological aging data, biomarkers are getting precise enough to measure them, and geroscience is getting specific enough to act on them. Put those together and you get something that looks less like 'wellness' and more like medicine.

Here's where I have to do the friend-who-just-learned-this part responsibly. None of these papers say there's a pill you should be taking. None of them recommend a protocol. The Cell synthesis is a roadmap; the Biogerontology piece is a philosophy-of-science check-in; the Midwest symposium is a field update; the Aging review is an industry forecast. They are, collectively, the field saying: we think we finally know what we're aiming at.

Two things are worth holding onto. First, the language of 'gerogenes vs. gerosuppressors' will probably show up in headlines a lot over the next few years — now you know what it means and where it came from. Second, when you see a longevity startup promising personalized aging therapy, the right question isn't 'does the science exist?' It's 'has this specific intervention been tested in a randomized trial in people like me?' That's the bar the Cell authors themselves set.

If any of this is exciting to you personally — say, you're thinking about supplements, screening, or a longevity clinic — the boring but correct move is to talk to a clinician who can look at your actual health picture. The whole point of precision geromedicine is that the answer depends on the person. We're not there yet at the pharmacy. But for the first time, the field seems to agree on the address.